Evolus (NASDAQ:EOLS) Reaches New 12-Month Low - Here's Why

Key Points

• Evolus, Inc. (NASDAQ:EOLS) shares reached a new **52-week low** of $8.65, with a recent trading price of $8.71 and a total volume of **311,804 shares** traded.
• Multiple analysts have reaffirmed a **"buy" rating** for Evolus, with target prices ranging from **$21.00 to $27.00**, suggesting a favorable outlook despite current stock performance.
• Insider buying activity has occurred, with **Director Albert G. White III** purchasing **20,000 shares** at approximately $9.45 each, increasing his stake in the company significantly.

Shares of Evolus, Inc. (NASDAQ:EOLS - Get Free Report) hit a new 52-week low during trading on Friday . The company traded as low as $8.65 and last traded at $8.71, with a volume of 311804 shares trading hands. The stock had previously closed at $8.92.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on EOLS. Needham & Company LLC reissued a "buy" rating and set a $22.00 price target on shares of Evolus in a research note on Thursday, May 8th. HC Wainwright reaffirmed a "buy" rating and issued a $27.00 price objective on shares of Evolus in a research note on Thursday, April 10th. Finally, BTIG Research initiated coverage on Evolus in a research note on Thursday, April 17th. They issued a "buy" rating and a $21.00 price objective on the stock. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $23.75.

Evolus Stock Performance

The stock has a 50 day moving average of $9.47 and a 200 day moving average of $11.28. The company has a quick ratio of 2.16, a current ratio of 2.34 and a debt-to-equity ratio of 22.00. The company has a market capitalization of $574.84 million, a price-to-earnings ratio of -10.05 and a beta of 1.12.

Insiders Place Their Bets

In other Evolus news, insider Rui Avelar sold 3,385 shares of Evolus stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $9.87, for a total value of $33,409.95. Following the completion of the sale, the insider directly owned 359,082 shares in the company, valued at approximately $3,544,139.34. The trade was a 0.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Sandra Beaver sold 6,494 shares of Evolus stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $10.02, for a total value of $65,069.88. Following the completion of the sale, the chief financial officer owned 167,089 shares of the company's stock, valued at approximately $1,674,231.78. The trade was a 3.74% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 153,571 shares of company stock valued at $1,537,090. Company insiders own 6.10% of the company's stock.

Institutional Investors Weigh In On Evolus

Several institutional investors have recently bought and sold shares of the stock. Tang Capital Management LLC grew its holdings in Evolus by 3.1% during the fourth quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company's stock worth $55,171,000 after buying an additional 150,000 shares in the last quarter. Vanguard Group Inc. grew its stake in Evolus by 2.0% in the 1st quarter. Vanguard Group Inc. now owns 3,234,068 shares of the company's stock valued at $38,906,000 after purchasing an additional 62,664 shares during the period. Nantahala Capital Management LLC grew its stake in Evolus by 10.8% in the 4th quarter. Nantahala Capital Management LLC now owns 3,130,149 shares of the company's stock valued at $34,557,000 after purchasing an additional 305,300 shares during the period. Caligan Partners LP grew its stake in Evolus by 22.7% in the 4th quarter. Caligan Partners LP now owns 2,692,388 shares of the company's stock valued at $29,724,000 after purchasing an additional 498,900 shares during the period. Finally, Millennium Management LLC grew its stake in Evolus by 1.7% in the 1st quarter. Millennium Management LLC now owns 1,392,028 shares of the company's stock valued at $16,746,000 after purchasing an additional 23,605 shares during the period. Institutional investors own 90.69% of the company's stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.